SLC5A2 and hydrops fetalis: Recently, sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a promising therapy for HFpEF, as the EMPEROR-Preserved trial demonstrated that empagliflozin reduces the risk of the composite cardiovascular (CV) endpoint of death or heart failure (HF) hospitalization in HF patients with LVEF > 40%[1].